P
P. Vedel
Researcher at Steno Diabetes Center
Publications - 12
Citations - 5603
P. Vedel is an academic researcher from Steno Diabetes Center. The author has contributed to research in topics: Type 2 diabetes & Microalbuminuria. The author has an hindex of 11, co-authored 12 publications receiving 5438 citations. Previous affiliations of P. Vedel include Novo Nordisk.
Papers
More filters
Journal ArticleDOI
Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes
Peter Gæde,P. Vedel,Nicolai Larsen,Nicolai Larsen,Jensen G,Hans-Henrik Parving,Hans-Henrik Parving,Oluf Pedersen,Oluf Pedersen +8 more
TL;DR: A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent.
Journal ArticleDOI
Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study
TL;DR: Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria slows progression to nephropathy, and progression of retinopathy and autonomic neuropathy.
Journal ArticleDOI
Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria
TL;DR: Remission to normo Albuminuria was associated with a decreased GFR decline during 7.8 years of follow-up in type 2 diabetic patients with microalbuminuria and antihypertensive therapy and improved glycaemic control were independent predictors for remission.
Journal ArticleDOI
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Journal ArticleDOI
Glomerular hyperfiltration in microalbuminuric NIDDM patients.
P. Vedel,J. Obel,Flemming S Nielsen,L. E. Bang,T. L. Svendsen,Oluf Pedersen,Hans-Henrik Parving +6 more
TL;DR: It is indicated that NIDDM patients at high risk of developing diabetic nephropathy are also characterized by an additional putative risk factor for progression, glomerular hyperfiltration.